Column Capital Advisors’s DexCom DXCM Stock Holding History

Column Capital Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$431K	Buy	4,617 +587	+15%	+$66.2K	0.06%	90
2023 Q2	$518K	Hold	4,030	–	–	0.07%	85
2023 Q1	$468K	Sell	4,030 -617	-13%	-$69.1K	0.07%	82
2022 Q4	$526K	Sell	4,647 -289	-6%	-$31.7K	0.09%	65
2022 Q3	$398K	Hold	4,936	–	–	0.08%	68
2022 Q2	$368K	Buy	4,936 +2,136	+76%	+$195K	0.07%	73
2022 Q1	$358K	Buy	2,800 +224	+9%	+$24.5K	0.07%	86
2021 Q4	$346K	Sell	2,576 -88	-3%	-$12.6K	0.07%	93
2021 Q3	$364K	Buy	2,664 +472	+22%	+$59.5K	0.08%	83
2021 Q2	$234K	Sell	2,192 -48	-2%	-$4.61K	0.05%	112
2021 Q1	$201K	Buy	2,240 +584	+35%	+$54.8K	0.04%	118
2020 Q4	$153K	Sell	1,656 -28	-2%	-$2.5K	0.04%	131
2020 Q3	$174K	Hold	1,684	–	–	0.05%	103
2020 Q2	$170K	Buy	+1,684	New	+$151K	0.06%	103

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Column Capital Advisors's DXCM Position: Q3 2023 in Review

Column Capital Advisors increased its DexCom (DXCM) stake by 15% in Q3 2023, buying an estimated $66.2K and bringing the position to 4,617 shares worth $431K. The position accounts for 0.06% of the portfolio, ranked #90.

Column Capital Advisors first reported a position in DXCM in Q2 2020 and has held it in 14 quarters since. The position peaked at $526K in Q4 2022. 902 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

Column Capital Advisors held 4,617 shares of DexCom worth $431K as of Q3 2023.
Column Capital Advisors bought 587 DexCom shares in Q3 2023, an estimated $66.2K.
DexCom made up 0.06% of Column Capital Advisors's portfolio in Q3 2023, its #90 holding.
Column Capital Advisors first reported a position in DexCom in Q2 2020 and has held it in 14 quarters since.
Column Capital Advisors's DexCom position peaked at $526K in Q4 2022.
902 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.